Physician profile
Bruce W Olin
NPI 1134116775
$8,355.32
in general payments reported to CMS, 2019-2025
42 companies · $824 in 2025
The $824 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,685 · 2020: $966 · 2021: $731 · 2022: $1,370 · 2023: $1,451 · 2024: $1,329 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,603.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,260.94 | 2019-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $881.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $736.11 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $646.84 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $536.64 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novartis Pharmaceuticals Corporation | $463.98 | 2019-2025 | |
| Abbvie INC. | $403.26 | 2021-2025 | |
| Lundbeck LLC | $398.63 | 2020-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $357.15 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $352.84 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $337.59 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $320.89 | 2019-2024 | Shingrix, Arexvy |
| Abbott Laboratories | $232.98 | 2021-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $157.49 | 2020-2025 | Eliquis, Camzyos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $152.25 | 2023-2025 | Caplyta |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Olin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.